Gallacher Capital Management LLC Purchases 150 Shares of AstraZeneca PLC (NASDAQ:AZN)

Gallacher Capital Management LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,431 shares of the company’s stock after acquiring an additional 150 shares during the period. Gallacher Capital Management LLC’s holdings in AstraZeneca were worth $368,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Hemenway Trust Co LLC bought a new stake in shares of AstraZeneca in the 1st quarter valued at about $323,000. Coulter & Justus Financial Services LLC bought a new stake in shares of AstraZeneca in the 1st quarter valued at $339,000. Geneos Wealth Management Inc. raised its stake in AstraZeneca by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 14,922 shares of the company’s stock worth $1,011,000 after buying an additional 4,573 shares during the last quarter. Signaturefd LLC boosted its position in AstraZeneca by 6.7% during the first quarter. Signaturefd LLC now owns 50,057 shares of the company’s stock valued at $3,391,000 after acquiring an additional 3,155 shares during the last quarter. Finally, Rehmann Capital Advisory Group raised its position in shares of AstraZeneca by 7.1% in the 1st quarter. Rehmann Capital Advisory Group now owns 8,258 shares of the company’s stock worth $560,000 after acquiring an additional 547 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Up 2.1 %

Shares of AZN stock traded up $1.65 on Friday, hitting $79.59. The stock had a trading volume of 1,443,268 shares, compared to its average volume of 5,395,919. The business has a 50 day moving average price of $78.11 and a 200 day moving average price of $71.07. AstraZeneca PLC has a one year low of $60.47 and a one year high of $80.86. The company has a market cap of $246.77 billion, a PE ratio of 38.21, a P/E/G ratio of 1.40 and a beta of 0.45. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. Research analysts anticipate that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on AZN shares. Barclays upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. BMO Capital Markets raised their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. The Goldman Sachs Group started coverage on shares of AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective on the stock. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Finally, Argus boosted their target price on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.